HK1040633A1 - Method of administering a compound to multi-drug resistant cells - Google Patents

Method of administering a compound to multi-drug resistant cells

Info

Publication number
HK1040633A1
HK1040633A1 HK02102308A HK02102308A HK1040633A1 HK 1040633 A1 HK1040633 A1 HK 1040633A1 HK 02102308 A HK02102308 A HK 02102308A HK 02102308 A HK02102308 A HK 02102308A HK 1040633 A1 HK1040633 A1 HK 1040633A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic compound
drug resistant
composition
administering
compound
Prior art date
Application number
HK02102308A
Other languages
English (en)
Inventor
Gabizon Alberto
Zalipsky Samuel
Goren-Rubel Dorit
Horowitz Aviva
Original Assignee
Alza Corp
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp, Hadasit Med Res Service filed Critical Alza Corp
Publication of HK1040633A1 publication Critical patent/HK1040633A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK02102308A 1998-12-18 2002-03-26 Method of administering a compound to multi-drug resistant cells HK1040633A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11300498P 1998-12-18 1998-12-18
PCT/US1999/030230 WO2000035422A2 (fr) 1998-12-18 1999-12-17 Procede d'administration d'un compose a des cellules resistant a plusieurs medicaments

Publications (1)

Publication Number Publication Date
HK1040633A1 true HK1040633A1 (en) 2002-06-21

Family

ID=22347057

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102308A HK1040633A1 (en) 1998-12-18 2002-03-26 Method of administering a compound to multi-drug resistant cells

Country Status (12)

Country Link
US (2) US20040161457A1 (fr)
EP (1) EP1140022B8 (fr)
JP (1) JP2002532407A (fr)
AT (1) ATE385778T1 (fr)
AU (1) AU769569B2 (fr)
CA (1) CA2353593A1 (fr)
DE (1) DE69938148T2 (fr)
ES (1) ES2302391T3 (fr)
HK (1) HK1040633A1 (fr)
IL (1) IL143555A0 (fr)
MX (1) MXPA01006201A (fr)
WO (1) WO2000035422A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
CA2404737C (fr) 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Substance pour l'administration d'un medicament, contenant du polyalkylene glycol et un phospholipide joints par covalence au medicament
JP4922824B2 (ja) * 2000-04-03 2012-04-25 参天製薬株式会社 送達性物質およびそれを利用した薬物デリバリーシステム
WO2004056323A2 (fr) * 2002-12-19 2004-07-08 Alza Corporation Methode de traitement de la croissance de tissu angiogenique
US7601332B2 (en) 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CN100423778C (zh) * 2003-11-25 2008-10-08 上海复旦张江生物医药股份有限公司 用于上载抗肿瘤药物的脂质体载体及其制备方法和应用
EP1789391B1 (fr) 2004-07-23 2017-06-28 Endocyte, Inc. Groupes de liaison bivalents et conjugués de ceux-ci
US20070292497A1 (en) * 2006-05-04 2007-12-20 Martin Francis J Method for treating micrometastatic tumors
AU2008224988A1 (en) 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
PL2308514T3 (pl) * 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2703491C (fr) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysines et leurs procedes de preparation
US20120100206A1 (en) 2009-06-11 2012-04-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
ES2819059T3 (es) 2011-07-13 2021-04-14 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Liposomas que encapsulan conjuntamente un bifosfonato y un agente anfipático
EP2789348B1 (fr) 2011-12-07 2021-08-04 Universidade do Minho Liposomes et procédé de production correspondant
WO2013126797A1 (fr) 2012-02-24 2013-08-29 Purdue Research Foundation Ciblage du récepteur de la cholécystokinine de type b pour imagerie et thérapie
GB201215289D0 (en) 2012-08-28 2012-10-10 Medical Res Council Nanoparticle formulation
US9950074B2 (en) * 2012-10-12 2018-04-24 Georg-August-Universität Göttingen Stiftung Öffenlichen Rechts, Universitätsmedizin Composition and delivery vehicle for active agents and methods therefor
SG11201502896XA (en) 2012-10-16 2015-05-28 Endocyte Inc Drug delivery conjugates containing unnatural amino acids and methods for using
CN106420615B (zh) * 2016-07-05 2021-01-05 广东药科大学 一种靶向脂质体骨架材料及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5804445A (en) * 1996-01-11 1998-09-08 Board Of Regents, The University Of Texas System High affinity mutants of nuclear factor-interleukin 6 and methods of use therefor
WO1998013072A1 (fr) * 1996-09-24 1998-04-02 Thomas Jefferson University Compositions et procedes destines au traitement de la resistance multiple aux anticancereux
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6162810A (en) * 1997-11-17 2000-12-19 The Regents Of The University Of California Inadone and tetralone compounds for inhibiting cell proliferation
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
IT1315253B1 (it) * 1999-10-22 2003-02-03 Novuspharma Spa Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato
PL1684763T3 (pl) * 2003-09-24 2008-11-28 Wyeth Corp 6-arylo-7-halogeno-imidazo[1,2-a]pirymidyny jako środki przeciwnowotworowe

Also Published As

Publication number Publication date
WO2000035422A2 (fr) 2000-06-22
EP1140022A2 (fr) 2001-10-10
ATE385778T1 (de) 2008-03-15
JP2002532407A (ja) 2002-10-02
DE69938148T2 (de) 2009-02-26
US20060062842A1 (en) 2006-03-23
MXPA01006201A (es) 2003-06-06
EP1140022B8 (fr) 2008-10-15
ES2302391T3 (es) 2008-07-01
AU1940400A (en) 2000-07-03
CA2353593A1 (fr) 2000-06-22
DE69938148D1 (de) 2008-03-27
WO2000035422A3 (fr) 2000-10-12
AU769569B2 (en) 2004-01-29
US20040161457A1 (en) 2004-08-19
IL143555A0 (en) 2002-04-21
EP1140022B1 (fr) 2008-02-13

Similar Documents

Publication Publication Date Title
EP1140022B8 (fr) Procede d'administration d'un compose a des cellules resistant a plusieurs medicaments
IL142573A0 (en) Liposome-entrapped topoisomerase inhibitors
WO1998016202B1 (fr) Composition a base de liposomes fusogenes et procede correspondant
WO1999039741A3 (fr) Administration systemique de particules lipidiques du plasmide stables dans le serum en cancerotherapie
CA2193502A1 (fr) Sphingosomes servant a ameliorer l'administration de medicaments
WO2000045792A8 (fr) Preparations de particules hydrogel
WO2000007979A3 (fr) Composes et compositions pour l'administration de principes actifs
AU5408098A (en) Oral morphine multiparticulate formulation
WO2002022000A3 (fr) Therapie par particules alpha ciblees utilisant des conjugues d'actinium-225
CA2338358A1 (fr) Composes permettant de delivrer des agents actifs et compositions a base de ces composes
WO2001080843A3 (fr) Inhibition d'une proliferation cellulaire anormale avec de la camptothecine et combinaisons contenant ledit compose
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
CA2628857A1 (fr) Preparation et methode de traitement de neoplasmes par inhalation
CA2122519A1 (fr) Traitement du cancer et prevention des metastases
CA2208206A1 (fr) Composition pour le traitement de tumeurs comprenant du lactose et un conjugue saccharidique d'un compose phenolique cytotoxique
EP2020237A3 (fr) Céramide et agents de chimiothérapie pour induire la mort cellulaire
WO1999013816A3 (fr) Compositions a base de liposomes renfermant de la camptothecine
CA2202531A1 (fr) Lyophilisat de complexe lipide de camptothecines non hydrosolubles
JP2002532407A5 (fr)
CA2108963A1 (fr) Compositions et methodes de traitement et de prevention du cancer, du sida et de l'anemie
WO1999022722A3 (fr) Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire
WO1998030709A3 (fr) Promedicaments non immunogenes et marqueurs capables d'etre selectionnes s'utilisant en therapie genique
Sharma et al. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers
CA2225807A1 (fr) Utilisation d'alcaloides de la classe lamellarine dans des procedes de traitement
ATE356637T1 (de) Supramolekulare komplexe enthaltende arzneimittel

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PE Patent expired

Effective date: 20191216